Qualigen Therapeutics

Qualigen Therapeutics (QLGN) shareholders approved a strategic shift to AIxCrypto Holdings (AIXC) by Nov 20, 2025. Faraday Future will become the majority shareholder (≈55% direct, ≈63% incl. affiliates) and nominate most board members before this date. The company approved share issuance, an equity incentive plan, and Nasdaq rule waivers. A new AI/Web3 business model and board will be revealed at the Nasdaq ceremony. This marks a transition from biotechnology into a decentralized AI technology platform.

Qualigen Therapeutics (QLGN) will launch C10 Cryptocurrency Asset Treasury (DAT) purchases next week. The company has established USD settlement and crypto custody accounts, but has not yet purchased any virtual currencies. QLGN views the recent crypto pullback as a deleveraging event and plans an 80/20 passive/active allocation for CXC10. They will also expand hedging tools, pursue strategic M&A, and promote C10 private and ETF products to grow assets under management. Previous market volatility included $16B in liquidations and ~$200B wiped from market cap.